Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

CUE 11.25.2024

Full Press ReleaseSEC FilingsOur CUE Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.29.2024 - Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • 11.25.2024 - Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.16.2024 - UPLOAD SEC-generated letter
  • 12.11.2024 - CORRESP Correspondence
PDF Version

BOSTON,Nov. 25, 2024(GLOBE NEWSWIRE) --Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held inNew York, NY,Dec 3-5, 2024.

During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.

Presentation DetailsDate and Time:Wednesday, December 4, 2024, from9 a.m. EST–9:25 a.m. ESTWebcast Link:https://event.webcasts.com/starthere.jsp?ei=1697351&tp_key=a82c532edcPresenter:Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company’s website atwww.cuebiopharma.com. The webcast will be archived for 30 days.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STATTM(Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston,Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visitwww.cuebiopharma.comand follow us onXandLinkedIn.

Investor ContactMarie CampinellSenior Director, Corporate CommunicationsCue Biopharma, Inc.mcampinell@cuebio.com

Media ContactJonathan PappasLifeSci Communicationsjpappas@lifescicomms.com

Primary Logo

Source: Cue Biopharma, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com